Literature DB >> 20457177

18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats.

Olga D Taraschenko1, Isabelle M Maisonneuve, Stanley D Glick.   

Abstract

18-Methoxycoronaridine (18-MC), a selective antagonist of alpha3beta4 nicotinic receptors, has been shown to reduce the self-administration of several drugs of abuse. Recently, this agent has also been shown to attenuate sucrose reward, decrease sucrose intake and prevent the development of sucrose-induced obesity in rats. The present experiments were designed to determine whether the latter effect was due to an 18-MC-induced conditioned taste aversion to sucrose. Both 18-MC (20mg/ kg, i.p.) and control agent, lithium chloride (100mg/kg, i.p.), reduced sucrose intake 24h after association with sucrose; however, only lithium chloride reduced sucrose intake 72h later. Consistent with previous data, 18-MC appears to have proactive effect for 24h and it does not induce a conditioned taste aversion. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457177      PMCID: PMC4575503          DOI: 10.1016/j.pbb.2010.05.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  23 in total

1.  Conditioned aversion to saccharin resulting from exposure to gamma radiation.

Authors:  J GARCIA; D J KIMELDORF; R A KOELLING
Journal:  Science       Date:  1955-07-22       Impact factor: 47.728

2.  Boosting cholinergic activity in gustatory cortex enhances the salience of a familiar conditioned stimulus in taste aversion learning.

Authors:  Emily Wilkins Clark; Ilene L Bernstein
Journal:  Behav Neurosci       Date:  2009-08       Impact factor: 1.912

3.  Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.

Authors:  Stanley D Glick; Isabelle M Maisonneuve; Barbara A Kitchen; Mark W Fleck
Journal:  Eur J Pharmacol       Date:  2002-03-01       Impact factor: 4.432

4.  Selective suppression of drinking during a limited period following aversive drug treatment in rats.

Authors:  M Domjan
Journal:  J Exp Psychol Anim Behav Process       Date:  1977-01

5.  18-MC reduces methamphetamine and nicotine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; H A Dickinson
Journal:  Neuroreport       Date:  2000-06-26       Impact factor: 1.837

6.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion.

Authors:  M Shoaib; J Gommans; A Morley; I P Stolerman; R Grailhe; J-P Changeux
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

7.  Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors are involved in mediating the ghrelin-induced locomotor stimulation and dopamine overflow in nucleus accumbens.

Authors:  Elisabet Jerlhag; Emil Egecioglu; Suzanne L Dickson; Lennart Svensson; Jörgen A Engel
Journal:  Eur Neuropsychopharmacol       Date:  2008-03-17       Impact factor: 4.600

Review 8.  Neural substrates for conditioned taste aversion in the rat.

Authors:  T Yamamoto; T Shimura; N Sako; Y Yasoshima; N Sakai
Journal:  Behav Brain Res       Date:  1994-12-15       Impact factor: 3.332

9.  Heterogeneity of nicotinic acetylcholine receptor expression in the caudal nucleus of the solitary tract.

Authors:  David V Smith; Victor V Uteshev
Journal:  Neuropharmacology       Date:  2007-11-05       Impact factor: 5.250

10.  Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.

Authors:  Isabelle M Maisonneuve; Stanley D Glick
Journal:  Pharmacol Biochem Behav       Date:  2003-06       Impact factor: 3.533

View more
  1 in total

1.  Effects of 18-methoxycoronaridine on ghrelin-induced increases in sucrose intake and accumbal dopamine overflow in female rats.

Authors:  Sarah E McCallum; Olga D Taraschenko; Ethan R Hathaway; Melanie Y Vincent; Stanley D Glick
Journal:  Psychopharmacology (Berl)       Date:  2011-01-06       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.